Latest News !
 

Commercialisation Australia - Mixed Reviews, 'Fabulous Logo'

Genetic Technologies CEO Dr Paul MacLeman
- The Hottest Seat In Biotech

Chemgenex - 'ASX's Most Undervalued Biotech'

BRIL Group Proposal For Commonwealth Commercialisation Institute - July 6, 2009

ASX In Wonderland III: Corporate Regulation

 

February BDI-40 Falls - Leads  S&P ASX200
Heartware Up 34%, Cathrx Down 47%  

March 1, 2010

 

Narrowly retaining its numerical lead over the ASX benchmark, the Biotech Daily Top 40 Index (BDI-40) fell 3.2 percent in February 2010, while the S&P ASX 200 climbed 1.5 percent. The BDI-20 fell 2.4 percent for the month, with the Second 20 down 7.7 percent.

 

But for the year to February 28, 2010, the BDI-40 was up 115.2 percent, compared to the ASX200 up 38.7 percent. The BDI-20 was up 118.6 percent for the year with the Second 20 up 97.5 percent.

 

The three Big Caps of Cochlear, CSL and Resmed, which are not included in the BDI-40, collectively gained 9.9 percent for the month – their biggest in more than a year - but were 7.2 percent lower than 12 months ago. Resmed climbed 10.8 percent to $4,911 million and CSL made its first significant gain since October 2009, up 11.7 percent for the month.

 

Twenty-six of the Top 40 biotechnology companies fell, with 16 falling more than 10 percent, while nine climbed, with five up by more than 10 percent.

 

Heartware was the best in February 2010, with a $71 million capital raising taking it up 34 percent to $603 million, followed by Clinuvel up 23.1 percent to $80 million, Tissue Therapies (19.2%), Phosphagenics (16.3%) and QRX (14.0%).

 

Virax was the best outside the Top 40 climbing 72.7 percent to $19 million, with Anteo up 37.5 percent to $22 million.

 

Cathrx led the falls, down 47.4 percent to $20 million, followed by Chemgenex down 27.4 percent to $193 million, Phylogica (26.9%), Bone (26.3%), Patrys (24.3%), Circadian (21.9%), Avexa (21.4%) and Novogen (21.3%).

 

Biotechs raised $80.6 million in February 2010 compared to the $5.45 million raised in February 2009, with more than $580 million raised in the year to February 28, 2010.

 

Despite a component problem (BD: Feb 26, 2010) Nanosonics has established itself as a successful innovator with product in the market and will be promoted to the Top 20, swapping with Phosphagenics which appears to be concentrating more on cosmetics than its transdermal human health applications.

 

Biotech Daily Top 40 ($m) v S&P ASX200 2009-'10